Introduction {#s1}
============

A novel strain of influenza A(H1N1)pdm09 virus was first detected in Mexico^[@DKT496C1]^ and the USA^[@DKT496C2],[@DKT496C3]^ in April 2009. After its initial detection, the pandemic virus spread to many parts of the world, including Canada.^[@DKT496C4]--[@DKT496C6]^ In British Columbia (BC), Canada, the first wave of A(H1N1)pdm09 activity during spring/summer of 2009 was limited, but was followed by a second, more substantial and widespread wave in the autumn that began in early October, peaked during the last week of October and resolved by the end of 2009.^[@DKT496C7],[@DKT496C8]^ Alongside other provinces of Canada, BC provided two pharmaceutical interventions free-of-charge as part of public health population efforts to mitigate overall impact of the pandemic: an AS03-adjuvanted vaccine as prevention and a neuraminidase inhibitor (NI) strategy as treatment.^[@DKT496C8]^

The adjuvanted A(H1N1)pdm09 vaccine used in Canada was ultimately shown to be highly effective (\>90%) against medically attended, laboratory-confirmed A(H1N1)pdm09 illness,^[@DKT496C9]^ but was delayed in availability such that initial administration coincided with the pandemic peak.^[@DKT496C8],[@DKT496C9]^ Prior to the pandemic, Canada had stockpiled antivirals, namely the two NIs oseltamivir and zanamivir, for treatment. In anticipation of the second pandemic wave, BC released and distributed NIs from its emergency stockpile for the treatment of people at high risk of influenza illness (regardless of severity) and for previously healthy people experiencing moderate-to-severe influenza-like illness (ILI). The former could also obtain prescriptions in advance to be filled in the event of ILI, minimizing delay from illness onset to the start of treatment. Ultimately, between the weeks of 4 October and 22 November 2009, \>120 000 NI prescriptions were filled in BC, with peak administration coinciding with other indicators of peak pandemic activity during the last week of October and the first week of November.^[@DKT496C8]^

Although NI stockpiles are a component of pandemic preparedness in most developed countries, the 2009 pandemic was the first pandemic for which widespread NI use was implemented on a population level with a goal of reducing serious disease and the associated healthcare burden. However, studies to assess antiviral effectiveness (AVE) against severe complications of influenza---seasonal or pandemic---remain largely lacking. Here, we assess AVE against hospitalization among patients clinically diagnosed with influenza during the autumn 2009 wave of A(H1N1)pdm09 in BC, Canada.

Methods {#s2}
=======

Study design and population {#s2a}
---------------------------

We conducted a retrospective cohort study using linked, administrative healthcare data extracted from the Medical Services Plan (MSP) billing information, the Hospital Separations and the *PharmaNet* prescription databases, provided by the BC Ministry of Health. Each eligible resident of BC is assigned a unique patient identifier, the personal health number, which is captured in all the databases and was used to link patients\' records across the various data files. The final anonymized dataset was sent to the BC Centre for Disease Control in Vancouver, BC, for analysis. This study received approval from the University of British Columbia Research Ethics Board.

The cohort(s) included all BC residents since 1 September 2009 with an outpatient clinical diagnosis of influenza defined by an MSP fee-service billing code specific for A(H1N1)pdm09 or referring to the International Classification of Diseases (ICD) 9th revision for influenza (ICD-9 code 487). The date of clinical influenza diagnosis became the referent for establishing exposure and outcome status. If the patient had more than one MSP diagnosis of influenza since 1 September, only the first was counted and used as the referent for both exposure and outcome classification.

The main study period spanned clinical influenza diagnosis during the dominant second-wave A(H1N1)pdm09 activity (1 October to 31 December 2009), with sensitivity analyses conducted around the more specific peak period (18 October to 7 November) and the broader, but less specific, autumn period (1 September to 31 December) commencing prior to substantial A(H1N1)pdm09 second-wave circulation in BC.

Antiviral exposure was defined by the filling of an NI (oseltamivir or zanamivir) prescription on the same referent date (day 0), as obtained from *PharmaNet*, a population-based prescription drug database that captures all outpatient prescription drugs dispensed in the province, regardless of the payer/insurer. The referent date was chosen in the absence of information on actual illness onset, recognizing that delay to medical visit and prescription would already tend to underestimate AVE. Those filling an NI prescription before or after the referent date were excluded.

The main outcome was all-cause hospitalization within 14 days of the referent date, obtained from the Hospital Separations database that includes records from all acute care inpatient visits and long-term care holding beds, extended care beds, rehabilitation beds and discharge planning units managed by hospitals. In addition to all-cause hospitalization, we explored outcomes of pneumonia or influenza (P&I; ICD-10 codes: J10--18) and acute respiratory diseases (ARD; ICD-10 codes: J00--06 and J20--22), including where these were coded as the primary cause or anywhere on the hospital discharge record.

Statistical analysis {#s2b}
--------------------

Cox proportional hazards models assessed AVE with 1 : 1 propensity score matching and covariate adjustment. Since the assignment of subjects to NI treatment and non-treatment groups was not random during the pandemic, confounding factors may bias treatment effects. Therefore, propensity score matching, estimated by multivariate logistic regression with the smallest Akaike\'s information criterion, was used to minimize such bias and balance the baseline and clinical characteristics between the two groups. One-to-one matching of NI-exposed to unexposed individuals based on the propensity score was performed by using the 'greedy nearest-neighbour' algorithm.^[@DKT496C10]^ Separate propensity score-matched cohorts were constructed for the main study period and sensitivity analyses.

Participant profiles and hospitalization incidences were derived by NI exposure status before and after propensity score matching, further stratified by relevant subgroups. Multivariable Cox regression analyses compared the hazard of hospitalization in NI-exposed subjects with the hazard of hospitalization in unexposed subjects in the propensity score-matched cohorts by the hazard ratio (HR), adjusted for relevant covariates (see below). AVE was derived as (1 − HR) × 100%.

The baseline covariates used in propensity score construction and Cox regression analysis included age (\<6 months, 6--11 months, 1--4 years, 5--9 years, 10--19 years, 20--49 years, 50--64 years, 65--79 years and ≥80 years), gender, health services delivery area, number of physician visits on the referent date (1 and ≥1), number of physician visits (0, 1, 2--4 and ≥5) and hospitalizations (0, 1, 2--3 and ≥4) within 6 months prior to the referent date, use of immunosuppressives within ±30 days of the referent date, cardiorespiratory conditions (myocardial infarction, congestive heart failure, chronic obstructive pulmonary disease, asthma, cystic fibrosis and bronchopulmonary dysplasia), immunosuppressive conditions (connective tissue disease--rheumatic disease, cancer, metastatic carcinoma and HIV), metabolic conditions (diabetes mellitus and other metabolic diseases), neurological conditions (stroke and other conditions) and other conditions (liver disease and renal disease). Covariates were entered into the model via a stepwise multivariate Cox regression model (entry criteria of *P* ≤ 0.1 and staying criteria of *P* ≤ 0.05) and some covariates were recategorized when needed.

Information on comorbid conditions was extracted according to diagnostic codes from the MSP database and Hospital Separations database within 2 years from the reference date (ICD-9/ICD-10 codes applied available upon request). Adjustment for comorbidity was dichotomized as 'yes'/'no' to any of the above chronic conditions, but also explored based on the Charlson index for which a score of 0 indicates no comorbidity.^[@DKT496C11]^ Patients considered immunosuppressed on the basis of therapy were defined by *PharmaNet* record of the following prescriptions: antirheumatic drugs, oral glucocorticoids, antirejection medication and chemotherapeutic agents.

Statistical significance in this study was defined as *P* ≤ 0.05. SAS version 9.2 (SAS, Cary, NC, USA) was used for all statistical analyses.

Results {#s3}
=======

Participants {#s3a}
------------

[Table S1 (available as Supplementary data at *JAC* Online)](http://jac.oxfordjournals.org/lookup/suppl/doi:10.1093/jac/dkt496/-/DC1) provides a summary of participant profiles before propensity score matching and Table [1](#DKT496TB1){ref-type="table"} after propensity score matching according to exposure and outcome status for the main analysis period of 1 October to 31 December 2009. Table [2](#DKT496TB2){ref-type="table"} compares hospitalization events by antiviral exposure for the main and sensitivity analyses before and after propensity score matching. Table 1.Participant profile by exposure and hospitalization, main analysis period (1 October to 31 December 2009), after propensity score matchingBaseline characteristics/categoryHospitalizedNot hospitalizedHospitalization rates per 1000 (95% CI)No NI (column %)NI (column %) (row %)overall (column %)*P* valueNo NI (column %)NI (column %) (row %)overall (column %)*P* valueNo NINIoverallAge \<6 months5 (1.4%)2 (0.7%) (28.6%)7 (1.1%)0.08897 (0.2%)96 (0.2%) (49.7%)193 (0.2%)1.00049.0 (20.4, 117.8)20.4 (5.1, 81.6)35.0 (16.7, 73.4) 6--11 months1 (0.3%)1 (0.3%) (50.0%)2 (0.3%)362 (0.6%)367 (0.6%) (50.3%)729 (0.6%)2.8 (0.4, 19.6)2.7 (0.4, 19.3)2.7 (0.7, 10.9) 1--4 years24 (7.0%)21 (6.9%) (46.7%)45 (6.9%)4825 (8.4%)4834 (8.4%) (50.0%)9659 (8.4%)4.9 (3.3, 7.4)4.3 (2.8, 6.6)4.6 (3.5, 6.2) 5--9 years25 (7.2%)18 (5.9%) (41.9%)43 (6.6%)7732 (13.4%)7754 (13.4%) (50.1%)15 486 (13.4%)3.2 (2.2, 4.8)2.3 (1.5, 3.7)2.8 (2.1, 3.7) 10--19 years36 (10.4%)26 (8.6%) (41.9%)62 (9.6%)12 207 (21.2%)12 175 (21.1%) (49.9%)24 382 (21.1%)2.9 (2.1, 4.1)2.1 (1.5, 3.1)2.5 (2.0, 3.3) 20--49 years174 (50.4%)138 (45.4%) (44.2%)312 (48.1%)24 531 (42.5%)24 587 (42.6%) (50.1%)49 118 (42.5%)7.0 (6.1, 8.2)5.6 (4.7, 6.6)6.3 (5.6, 7.1) 50--64 years57 (16.5%)52 (17.1%) (47.7%)109 (16.8%)6111 (10.6%)6108 (10.6%) (50.0%)12 219 (10.6%)9.2 (7.1, 12.0)8.4 (6.4, 11.1)8.8 (7.3, 10.7) 65--79 years14 (4.1%)28 (9.2%) (66.7%)42 (6.5%)1510 (2.6%)1507 (2.6%) (50.0%)3017 (2.6%)9.2 (5.4, 15.5)18.2 (12.6, 26.4)13.7 (10.1, 18.6) ≥80 years9 (2.6%)18 (5.9%) (66.7%)27 (4.2%)341 (0.6%)329 (0.6%) (49.1%)670 (0.6%)25.7 (13.4, 49.4)51.9 (32.7, 82.3)38.7 (26.6, 56.5)Sex female215 (62.3%)181 (59.5%) (45.7%)396 (61.0%)0.46931 541 (54.6%)31 612 (54.7%) (50.1%)63 153 (54.7%)0.7746.8 (5.9, 7.7)5.7 (4.9, 6.6)6.2 (5.6, 6.9) male130 (37.7%)123 (40.5%) (48.6%)253 (39.0%)26 175 (45.4%)26 145 (45.3%) (50.0%)52 320 (45.3%)4.9 (4.2, 5.9)4.7 (3.9, 5.6)4.8 (4.3, 5.4)Immunosuppressive drug use yes39 (11.3%)50 (16.4%) (56.2%)89 (13.7%)0.0571485 (2.6%)1520 (2.6%) (50.6%)3005 (2.6%)0.53125.6 (18.7, 35.0)31.8 (24.1, 42.0)28.8 (23.4, 35.4) no306 (88.7%)254 (83.6%) (45.4%)560 (86.3%)56 231 (97.4%)56 237 (97.4%) (50.0%)112 468 (97.4%)5.4 (4.8, 6.1)4.5 (4.0, 5.1)5.0 (4.6, 5.4)No. of same-day GP visits 1309 (89.6%)289 (95.1%) (48.3%)598 (92.1%)0.00957 452 (99.5%)57 455 (99.5%) (50.0%)114 907 (99.5%)0.1115.3 (4.8, 6.0)5.0 (4.5, 5.6)5.2 (4.8, 5.6) 232 (9.3%)12 (3.9%) (27.3%)44 (6.8%)263 (0.5%)298 (0.5%) (53.1%)561 (0.5%)108.5 (76.7, 153.4)38.7 (22.0, 68.2)72.7 (54.1, 97.7) ≥34 (1.2%)3 (1.0%) (42.9%)7 (1.1%)1 (0.0%)4 (0.0%) (80.0%)5 (0.0%)800.0 (300.2, 2131.6)428.6 (138.2, 1328.8)583.3 (278.1, 1223.6)No. of past GP visits 0321 (93.0%)295 (97.0%) (47.9%)616 (94.9%)0.09556 975 (98.7%)57 051 (98.8%) (50.0%)114 026 (98.7%)0.5285.6 (5.0, 6.3)5.1 (4.6, 5.8)5.4 (5.0, 5.8) 117 (4.9%)5 (1.6%) (22.7%)22 (3.4%)592 (1.0%)569 (1.0%) (49.0%)1161 (1.0%)27.9 (17.4, 44.9)8.7 (3.6, 20.9)18.6 (12.2, 28.2) 2--45 (1.4%)2 (0.7%) (28.6%)7 (1.1%)127 (0.2%)110 (0.2%) (46.4%)237 (0.2%)37.9 (15.8, 91.0)17.9 (4.5, 71.4)28.7 (13.7, 60.2) ≥52 (0.6%)2 (0.7%) (50.0%)4 (0.6%)22 (0.0%)27 (0.0%) (55.1%)49 (0.0%)83.3 (20.8, 333.2)69.0 (17.2, 275.8)75.5 (28.3, 201.1)No. of past hospitalizations 0271 (78.6%)239 (78.6%) (46.9%)510 (78.6%)0.63254 581 (94.6%)54 640 (94.6%) (50.0%)109 221 (94.6%)0.7584.9 (4.4, 5.6)4.4 (3.8, 4.9)4.6 (4.3, 5.1) 147 (13.6%)39 (12.8%) (45.3%)86 (13.3%)2711 (4.7%)2692 (4.7%) (49.8%)5403 (4.7%)17.0 (12.8, 22.7)14.3 (10.4, 19.5)15.7 (12.7, 19.4) 2--319 (5.5%)22 (7.2%) (53.7%)41 (6.3%)397 (0.7%)390 (0.7%) (49.6%)787 (0.7%)45.7 (29.1, 71.6)53.4 (35.2, 81.1)49.5 (36.5, 67.2) ≥48 (2.3%)4 (1.3%) (33.3%)12 (1.8%)27 (0.0%)35 (0.1%) (56.5%)62 (0.1%)228.6 (114.3, 457.1)102.6 (38.5, 273.3)162.2 (92.1, 285.5)Charlson index 0247 (71.6%)230 (75.7%) (48.2%)477 (73.5%)0.31154 275 (94.0%)54 244 (93.9%) (50.0%)108 519 (94.0%)0.1954.5 (4.0, 5.1)4.2 (3.7, 4.8)4.4 (4.0, 4.8) 1--276 (22.0%)59 (19.4%) (43.7%)135 (20.8%)3155 (5.5%)3195 (5.5%) (50.3%)6350 (5.5%)23.5 (18.8, 29.5)18.1 (14.0, 23.4)20.8 (17.6, 24.6) 3--513 (3.8%)13 (4.3%) (50.0%)26 (4.0%)213 (0.4%)252 (0.4%) (54.2%)465 (0.4%)57.5 (33.4, 99.1)49.1 (28.5, 84.5)53.0 (36.1, 77.8) 6--98 (2.3%)2 (0.7%) (20.0%)10 (1.5%)72 (0.1%)62 (0.1%) (46.3%)134 (0.1%)100.0 (50.0, 200.0)31.3 (7.8, 125.0)69.4 (37.4, 129.1) ≥101 (0.3%)0 (0.0%) (0.0%)1 (0.2%)1 (0.0%)4 (0.0%) (80.0%)5 (0.0%)500.0 (70.4, 3549.7)0166.7 (23.5, 1183.2)Age/Charlson index \<6 months/≥15 (1.4%)2 (0.7%) (28.6%)7 (1.1%)\<0.00197 (0.2%)95 (0.2%) (49.5%)192 (0.2%)\<0.00149.0 (20.4, 117.8)20.6 (5.2, 82.4)35.2 (16.8, 73.8) 6--11 months/00 (0.0%)0 (0.0%) (0.0%)0 (0.0%)0 (0.0%)1 (0.0%) (100.0%)1 (0.0%)--------- \<6 months/01 (0.3%)1 (0.3%) (50.0%)2 (0.3%)354 (0.6%)362 (0.6%) (50.6%)716 (0.6%)2.8 (0.4, 20.0)2.8 (0.4, 19.6)2.8 (0.7, 11.1) 6--11 months/≥10 (0.0%)0 (0.0%) (0.0%)0 (0.0%)8 (0.0%)5 (0.0%) (38.5%)13 (0.0%)--------- 1--4 years/019 (5.5%)17 (5.6%) (47.2%)36 (5.5%)4515 (7.8%)4515 (7.8%) (50.0%)9030 (7.8%)4.2 (2.7, 6.6)3.8 (2.3, 6.0)4.0 (2.9, 5.5) 1--4 years/≥15 (1.4%)4 (1.3%) (44.4%)9 (1.4%)310 (0.5%)319 (0.6%) (50.7%)629 (0.5%)15.9 (6.6, 38.1)12.4 (4.6, 33.0)14.1 (7.3, 27.1) 5--9 years/014 (4.1%)11 (3.6%) (44.0%)25 (3.9%)7242 (12.5%)7247 (12.5%) (50.0%)14 489 (12.5%)1.9 (1.1, 3.3)1.5 (0.8, 2.7)1.7 (1.2, 2.5) 5--9 years/≥111 (3.2%)7 (2.3%) (38.9%)18 (2.8%)490 (0.8%)507 (0.9%) (50.9%)997 (0.9%)22.0 (12.2, 39.6)13.6 (6.5, 28.6)17.7 (11.2, 28.1) 10--19 years/030 (8.7%)23 (7.6%) (43.4%)53 (8.2%)11 760 (20.4%)11 725 (20.3%) (49.9%)23 485 (20.3%)2.5 (1.8, 3.6)2.0 (1.3, 2.9)2.3 (1.7, 2.9) 10--19 years/≥16 (1.7%)3 (1.0%) (33.3%)9 (1.4%)447 (0.8%)450 (0.8%) (50.2%)897 (0.8%)13.2 (6.0, 29.5)6.6 (2.1, 20.5)9.9 (5.2, 19.1) 20--49 years/0137 (39.7%)119 (39.1%) (46.5%)256 (39.4%)23 437 (40.6%)23 465 (40.6%) (50.0%)46 902 (40.6%)5.8 (4.9, 6.9)5.0 (4.2, 6.0)5.4 (4.8, 6.1) 20--49 years/≥137 (10.7%)19 (6.3%) (33.9%)56 (8.6%)1094 (1.9%)1122 (1.9%) (50.6%)2216 (1.9%)32.7 (23.7, 45.2)16.7 (10.6, 26.1)24.6 (19.0, 32.0) 50--64 years/034 (9.9%)28 (9.2%) (45.2%)62 (9.6%)5472 (9.5%)5462 (9.5%) (50.0%)10 934 (9.5%)6.2 (4.4, 8.6)5.1 (3.5, 7.4)5.6 (4.4, 7.2) 50--64 years/≥123 (6.7%)24 (7.9%) (51.1%)47 (7.2%)639 (1.1%)646 (1.1%) (50.3%)1285 (1.1%)34.7 (23.1, 52.3)35.8 (24.0, 53.4)35.3 (26.5, 47.0) 65--79 years/04 (1.2%)18 (5.9%) (81.8%)22 (3.4%)1160 (2.0%)1154 (2.0%) (49.9%)2314 (2.0%)3.4 (1.3, 9.2)15.4 (9.7, 24.4)9.4 (6.2, 14.3) 65--79 years/≥110 (2.9%)10 (3.3%) (50.0%)20 (3.1%)350 (0.6%)353 (0.6%) (50.2%)703 (0.6%)27.8 (14.9, 51.6)27.5 (14.8, 51.2)27.7 (17.8, 42.9) ≥80 years/03 (0.9%)11 (3.6%) (78.6%)14 (2.2%)238 (0.4%)219 (0.4%) (47.9%)457 (0.4%)12.4 (4.0, 38.6)47.8 (26.5, 86.4)29.7 (17.6, 50.2) ≥80 years/≥16 (1.7%)7 (2.3%) (53.8%)13 (2.0%)103 (0.2%)110 (0.2%) (51.6%)213 (0.2%)55.0 (24.7, 122.5)59.8 (28.5, 125.5)57.5 (33.4, 99.1) Table 2.Crude all-cause hospitalization and death rate per 100 000 person-days by antiviral exposure status and analysis period before and after propensity score matchingTime periodOutcomeAntiviral exposureBefore propensity score matchingAfter propensity score matching*n*no. of eventsperson-daysrate (95% CI)*n*no. of eventsperson-daysrate (95% CI)Main period (1 October to 31 December)hospitalizationtotal213 02213432 969 75645.22 (42.87, 47.71)116 1226491 619 56940.07 (37.10, 43.28)antiviral58 271310812 94538.13 (34.12, 42.62)58 061304810 08737.53 (33.54, 41.99)no antiviral154 75110332 156 81147.89 (45.06, 50.91)58 061345809 48242.62 (38.35, 47.36)deathtotal213 0221246 388 5121.94 (1.63, 2.31)116 122283 483 1600.80 (0.56, 1.16)antiviral58 271111 747 9380.63 (0.35, 1.14)58 061111 741 6380.63 (0.35, 1.14)no antiviral154 7511134 640 5742.44 (2.03, 2.93)58 061171 741 5220.98 (0.61, 1.57)Sensitivity analysis peak period (18 October to 7 November)hospitalizationtotal115 0377241 603 76245.14 (41.97, 48.55)73 5423801 025 98537.04 (33.49, 40.96)antiviral36 962184515 75535.68 (30.88, 41.22)36 771175513 18834.10 (29.40, 39.55)no antiviral78 0755401 088 00749.63 (45.62, 54.00)36 771205512 79739.98 (34.86, 45.84)deathtotal115 037603 450 0171.74 (1.35, 2.24)73 542152 205 9720.68 (0.41, 1.13)antiviral36 96271 108 7260.63 (0.30, 1.32)36 77171 102 9960.63 (0.30, 1.33)no antiviral78 075532 341 2912.26 (1.73, 2.96)36 77181 102 9760.73 (0.36, 1.45) full autumn (1 September to 31 December)hospitalizationtotal217 25213983 028 41546.16 (43.81, 48.65)117 5506681 639 26440.75 (37.77, 43.96)antiviral58 978317822 79038.53 (34.51, 43.01)58 775310820 03937.80 (33.82, 42.25)no antiviral158 27410812 205 62549.01 (46.17, 52.02)58 775358819 22543.70 (39.40, 48.47)deathtotal217 2521346 515 2142.06 (1.74, 2.44)117 550313 525 9740.88 (0.62, 1.25)antiviral58 978111 769 1480.62 (0.34, 1.12)58 775111 763 0580.62 (0.35, 1.13)no antiviral158 2741234 746 0662.59 (2.17, 3.09)58 775201 762 9161.13 (0.73, 1.76)

There were 227 755 people who had a physician visit related to influenza between 1 September and 31 December 2009 (Figure [1](#DKT496F1){ref-type="fig"}). Of those, 10 503 (4.6%) were removed due to missing information (*n *= 568) or because they filled an NI prescription after the referent date (*n* = 9935). Of the remaining 217 252 subjects, 27% (*n* = 58 978, only 86 were given zanamivir) met NI exposure criteria. The propensity score-matched cohort for the broadest period (1 September to 31 December 2009) included 58 775 records per exposure group (a total of 203 NI-treated subjects were removed due to extreme propensity scores or no matching from the non-NI-treated pool). For the main analysis period spanning 1 October to 31 December 2009, there were 58 061 per group; for the most specific pandemic peak period spanning 18 October to 7 November, there were 36 771 records per group. Figure 1.Propensity score matching cohort flow chart during second wave.

Before propensity score matching, the two cohorts (NI exposed and unexposed) differed significantly on almost all baseline characteristics (11 showed a *P* value of \<0.0002 and only cardiorespiratory condition had a *P* value of 0.7). These variables were used to derive propensity scores upon which the treatment groups were individually matched in each analysis period. After 1 : 1 propensity score matching, no baseline characteristics, including those considered as possible confounders, showed significant differences between groups. The distribution of all baseline covariates was completely balanced between NI-exposed and unexposed groups by the propensity score matching. Since only 203 subjects (0.03%) from the NI-treated subjects were lost during the matching algorithm, the final matching sample retains the representativeness of the population. Both before and after propensity score matching, data showed similar patterns in NI-exposed and unexposed groups with respect to the distribution of intervals between influenza visit and subsequent hospitalization. More than 50% of hospitalized subjects were admitted by day 3.

Overall and among subjects in both NI-exposed and unexposed groups, the highest hospitalization rates after propensity score matching were in the very young (\<6 months old) as well as the old (65--79 years old) and the very old (≥80 years old) (Table [1](#DKT496TB1){ref-type="table"}). Overall rates of hospitalization per 1000 patients in the exposed and unexposed cohorts, within 2weeks of an outpatient influenza diagnosis, were significantly higher in these age groups than in any other: 35.0 (95% CI 16.7--73.4), 13.7 (95% CI 10.1--18.6) and 38.7 (95% CI 26.6--56.5), respectively (Table [1](#DKT496TB1){ref-type="table"}). These ages comprised 0.2%, 2.6% and 0.6% of participants with outpatient influenza diagnosis.

About 6% of subjects with an outpatient physician diagnosis of influenza who were not subsequently hospitalized (i.e. within 14 days) had an underlying comorbidity (Table [1](#DKT496TB1){ref-type="table"}). Conversely, among hospitalized patients, about one-quarter of the exposed and unexposed groups had an underlying comorbidity and this was mainly due to age groups 20--49 and 50--64 years.

AVE {#s3b}
---

The crude and adjusted baseline HRs and the 95% CIs for all-cause hospitalization associated with the use of antivirals are illustrated in Table [3](#DKT496TB3){ref-type="table"}. During the main analysis period (Table [4](#DKT496TB4){ref-type="table"}), spanning 1 October to 31 December 2009, antivirals were associated with a statistically significant reduction of 16.1% in the risk of hospitalization (HR 0.839; 95% CI 0.719--0.980), comparable to the narrower, but more specific, pandemic peak period of 18 October to 7 November 2009 (AVE 15%; 95% CI −4%--30%). For the broader, but less specific, period spanning 1 September to 31 December 2009, AVE was higher (36%; 95% CI 20%--49%), but there was greater variability in this estimate. During the main analysis period, the use of more specific causes of hospitalization (P&I or ARD) also paradoxically resulted in lower AVE estimates.Table 3.Crude and adjusted HR for all-cause hospitalization, main analysis period (1 October to 31 December 2009)HR (95% CI)*P* valueCrude estimate0.881 (0.755, 1.027)0.1061Individual covariate adjustment age group0.881 (0.755, 1.028)0.1067 gender0.880 (0.755, 1.027)0.1053 health authority0.880 (0.754, 1.027)0.1047 immunosuppressive agent use0.877 (0.752, 1.024)0.0964 number of past GP visits0.883 (0.756, 1.030)0.1123 number of past hospitalizations0.881 (0.755, 1.028)0.1071 number of same-day GP visits0.738 (0.590, 0.923)^a^0.0078 Charlson index0.743 (0.594, 0.929)^a^0.0093 vaccine availability^b^0.864 (0.740, 1.009)0.0643Fully adjusted estimate0.839 (0.719, 0.980)0.0270[^1][^2][^3] Table 4.Main and sensitivity analyses of antiviral effectiveness by outcomeHR (95% CI) (*P* value)1 October to 31 December 2009 (main period)1 September to 31 December 2009 (second wave)18 October to 7 November 2009 (peak period)All-cause hospitalizations* n* (no. of hospitalizations) AV58 061 (304)58 775 (310)36 771 (175)* n* (no. of hospitalizations) non-AV58 061 (345)58 775 (358)36 771 (205)* *HR estimates crude0.881 (0.755, 1.027) (0.11)0.674 (0.542, 0.839)^a^ (\<0.01)0.853 (0.697, 1.044) (0.12)* *fully adjusted0.839 (0.719, 0.980) (0.03)0.639 (0.513, 0.796)^a^ (\<0.01)0.850 (0.695, 1.041) (0.12)Primary due to P & I* n* (no. of hospitalizations) AV58 061 (57)58 775 (59)36 771 (34)* n* (no. of hospitalizations) non-AV58 061 (40)58 775 (47)36 771 (32)* *HR estimates crude1.425 (0.951, 2.135) (0.09)1.255 (0.856, 1.841) (0.24)1.062 (0.656, 1.722) (0.81)* *fully adjusted1.421 (0.947, 2.131) (0.09)1.221 (0.832, 1.793) (0.31)1.035 (0.638, 1.679) (0.89)Due to P & I (anywhere on discharge sheet)* n* (no. of hospitalizations) AV58 061 (77)58 775 (79)36 771 (47)* n* (no. of hospitalizations) non-AV58 061 (71)58 775 (81)36 771 (56)* *HR estimates crude1.084 (0.785, 1.497) (0.62)0.975 (0.715, 1.329) (0.87)0.839 (0.570, 1.237) (0.38)* *fully adjusted1.041 (0.753, 1.440) (0.81)0.935 (0.685, 1.275) (0.67)0.808 (0.548, 1.191) (0.28)Primary due to acute respiratory diseases* n* (no. of hospitalizations) AV58 061 (11)58 775 (12)36 771 (6)* n* (no. of hospitalizations) non-AV58 061 (11)58 775 (11)36 771 (4)* *HR estimates crude1.000 (0.434, 2.307) (1.00)1.091 (0.481, 2.472) (0.84)1.500 (0.423, 5.315) (0.53)* *fully adjusted0.975 (0.422, 2.249) (0.95)1.078 (0.476, 2.444) (0.86)1.475 (0.416, 5.228) (0.55)Due to acute respiratory diseases (anywhere on discharge sheet)* n* (no. of hospitalizations) AV58 061 (18)58 775 (19)36 771 (9)* n* (no. of hospitalizations) non-AV58 061 (18)58 775 (15)36 771 (8)* *HR estimates crude1.385 (0.678, 2.826) (0.37)1.267 (0.644, 2.493) (0.49)1.125 (0.434, 2.915) (0.81)* *fully adjusted1.350 (0.661, 2.756) (0.41)1.239 (0.629, 2.440) (0.54)1.130 (0.436, 2.929) (0.80)Primary due to P & I and acute respiratory diseases* n* (no. of hospitalizations) AV58 061 (67)58 775 (70)36 771 (39)* n* (no. of hospitalizations) non-AV58 061 (51)58 775 (58)36 771 (36)* *HR estimates crude1.314 (0.913, 1.891) (0.14)0.887 (0.564, 1.396)^a^ (0.61)1.083 (0.689, 1.704) (0.73)* *fully adjusted1.257 (0.873, 1.812) (0.22)0.845 (0.536, 1.331)^a^ (0.47)1.076 (0.684, 1.693) (0.75)Due to P & I and acute respiratory diseases (anywhere on discharge sheet)* n* (no. of hospitalizations) AV58 061 (91)58 775 (94)36 771 (54)* n* (no. of hospitalizations) non-AV58 061 (84)58 775 (96)36 771 (64)* *HR estimates crude0.816 (0.560, 1.189)^a^ (0.29)0.734 (0.505, 1.069)^a^ (0.11)0.844 (0.587, 1.212) (0.36)* *fully adjusted0.772 (0.529, 1.127)^a^ (0.18)0.690 (0.474, 1.006)^a^ (0.054)0.807 (0.562, 1.160) (0.25)[^4][^5]

For the main analysis period, crude AVE among those with comorbidity was significant at 52% (95% CI 29%--68%) as was the fully adjusted model (59%; 95% CI 39%--73%). For those individuals without comorbidity, the crude and the fully adjusted AVE were non-significant at 6% (95% CI −14%--20%) and 6% (95% CI −13%--21%), respectively.

Discussion {#s4}
==========

Our large, population-based study found that antiviral use, as measured by receipt of a prescription for oseltamivir or zanamivir after a physician diagnosis of influenza or A(H1N1)pdm09 pandemic, was associated with a 15%--36% decrease in all-cause hospitalization. Our study is unique in that we used a population-based cohort to evaluate the effectiveness of antivirals; few studies have evaluated AVE in an entire cohort^[@DKT496C12],[@DKT496C13]^ and most used case series.^[@DKT496C14]--[@DKT496C18]^ Nevertheless, our results are consistent with other findings that show that NIs are useful during pandemics when taken within the recommended 48 h. These results support the use of antiviral medications as a key mitigation strategy.

Although the A(H1N1)pdm09 pandemic virus was more likely to infect the younger population, previous studies have showed that when patients aged ≥65 years were infected with influenza, they were more likely to be admitted into hospital and die from it.^[@DKT496C19]^ Our findings were similar and we saw the highest hospitalization rates in the very young (i.e. \<6 months of age) and in older adults (i.e. ≥65 years of age). About 6% of subjects with an outpatient physician diagnosis of influenza who were not subsequently hospitalized (i.e. within 14 days) had an underlying comorbidity (Table [1](#DKT496TB1){ref-type="table"}). Conversely, among hospitalized patients, about one-quarter of the treated and untreated groups had an underlying comorbidity. This high proportion was mainly contributed by adults, particularly those in age groups 20--49 and 50--64 years.

As mentioned previously, a number of studies, mostly case series, have evaluated the benefit of antivirals in reducing the severity of infections (reduction in critical care admission), hospitalizations and mortality during the 2009 pandemic.^[@DKT496C12],[@DKT496C14]--[@DKT496C18],[@DKT496C20],[@DKT496C21]^ Of note, the majority of these studies have been conducted in pregnant women.^[@DKT496C15]--[@DKT496C18],[@DKT496C20],[@DKT496C21]^ Like our study, they all demonstrated that NIs decreased the risk of severe disease and hospitalization. Our study databases could not identify pregnant women as a separate category as there was a lack of appropriate ICD-9 or -10 diagnostic codes to identify pregnancy during the pandemic. It would have been interesting to see the effect of the antivirals on this population, given that they are at higher risk of hospitalization and severe disease from influenza.^[@DKT496C15],[@DKT496C20],[@DKT496C21]^ A few of our patients did go to ICU, but the sample size was not large enough to do propensity score matching for the exposed and unexposed groups; thus, the data are not presented.

Early on in the 2009 pandemic, BC developed a targeted programme to encourage antiviral use in people with severe ILI disease and/or underlying chronic conditions. In our study, we saw that these patients were ≥30% more likely to receive antivirals. The provincial stockpile of NIs was also pre-distributed across the province to pharmacies and remote communities, so that people at risk could have access to the medications in a timely way. This study supports the benefits of this targeted approach to those at highest risk and the strategy of antiviral pre-distribution. In mitigating the pandemic impact, the avoidance of between 16% and 36% of hospitalizations attributable to the antiviral strategy was likely a key factor in the ability of the healthcare system to cope with the peak of infections between October and November 2009, before vaccine was available.

There are several limitations to this study. First, the measure of antiviral exposure we used was a prescription for antivirals being dispensed to an individual on day 0 with the assumption that the patients had symptoms for \<48 h prior to their physician visit. During our vaccine effectiveness analysis,^[@DKT496C9]^ the median time from ILI onset to physician visit was 2--3 days and therefore we may have included patients who had had symptoms for \>48 h prior to their physician visit; however, if this was the case, AVE would be higher than we observed. Further, we cannot be certain that the medication was actually taken by the recipient or that it was taken for a complete course. We are assuming that all the A(H1N1)pdm09 pandemic viruses were NI susceptible, but it should be noted that oseltamivir resistance is present in many countries and, as of 26 January 2011, 340 instances of oseltamivir resistance have been reported by the WHO Global Influenza Surveillance Network.^[@DKT496C22],[@DKT496C23]^

Individuals may have received antivirals from sources other than a pharmacy and these would not be recorded in the *PharmaNet* database. This was a potential primarily in remote communities where antivirals were pre-positioned within the community to be dispensed by the local healthcare worker. In addition, *PharmaNet* would not have recorded antiviral use for inmates in federal penitentiaries. Additionally, some people would have received a prescription from their physician in advance of the pandemic to be taken should they develop ILI. This was part of a campaign to ensure people at risk had a plan for assessment (often by phone) and treatment should they develop influenza during the pandemic. In either case, failure to capture these individuals would lead to conservative bias and an underassessment of AVE. Oseltamivir may have been administered to the 'healthier' population; a proxy for this could have been past vaccinations. Unfortunately, our merged datasets did not include past vaccinations as we do not have a complete immunization registry for adults. However, we did adjust for the 'healthy' adults by the number of past GP visits as well as the number of past hospitalizations.

Miscoding is always a possibility when using administrative data, especially when related to coding for physician office visits or hospitalization. This could have resulted in an over- or underestimation of AVE. This is particularly true for the varying estimates of AVE seen when we looked at more influenza-specific causes of hospitalizations, such as acute respiratory disease and/or pneumonia. Hospital emergency departments in BC use both physicians who bill for their services and those who are paid a flat fee. As such, if only an outpatient visit was required and the patient was seen by a non-billing physician, we would have not included them in our dataset.

Prior to the pandemic, randomized controlled trials evaluating the efficacy of antivirals for treatment of seasonal influenza A or B had shown them to shorten the course of illness when administered within 48 h of onset of illness,^[@DKT496C24]--[@DKT496C30]^ although the benefit was greatest when treatment was initiated with 12 h of the onset of symptoms.^[@DKT496C31]^ The use of antivirals in high-risk patients, defined as those over the age of 65 years or with chronic medical conditions, showed that they reduced the time to alleviation of symptoms by ∼0.5--1 day.^[@DKT496C32]^ Although these studies showed a modest decrease in symptom duration, not many studies had evaluated antiviral efficacy in preventing hospitalization or mortality. A pooled analysis of 10 randomized controlled trials of oseltamivir used in adults with acute influenza showed that its use was associated with a 50% decline in the hospitalization rate or lower respiratory infections and antibiotic use declined by 26%.^[@DKT496C33]^

Numerous studies have now been published on the A(H1N1)pdm09 pandemic, but most of these looked at risk factors associated with pH1N1. These studies showed that patients at increased risk of hospitalization^[@DKT496C6],[@DKT496C19],[@DKT496C34]--[@DKT496C37]^ and severe disease from pH1N1 were those with underlying medical conditions (especially asthma and chronic obstructive pulmonary disease),^[@DKT496C6],[@DKT496C14],[@DKT496C19],[@DKT496C32]--[@DKT496C35]^ children \<2 years of age (especially those with asthma and neurological conditions),^[@DKT496C14],[@DKT496C19],[@DKT496C38],[@DKT496C39]^ obese patients (BMI \>35),^[@DKT496C40]--[@DKT496C42]^ pregnant women^[@DKT496C15],[@DKT496C20],[@DKT496C21]^ and aboriginal peoples.^[@DKT496C6],[@DKT496C39],[@DKT496C43]^

The adjuvanted A(H1N1)pdm09 vaccine used in Canada was ultimately shown to be highly effective (\>90%) against medically attended, laboratory-confirmed A(H1N1)pdm09 illness,^[@DKT496C9]^ but was delayed in availability such that initial administration coincided with the pandemic peak in BC. Further, the vaccine was initially available in only limited amounts, requiring sequenced rollout beginning in the last week of October for persons with comorbidity \<65 years of age, pregnant women and remote community residents, followed by children \<5 years of age, healthcare workers and other caregivers \<65 years in early November, then older children and first responders and, finally, all other BC residents beginning mid--late November. Uptake of the vaccine was ∼35%--45% in the province overall and was highest in the elderly (age ≥65 years) in whom vaccine administration had been most delayed.^[@DKT496C8]^ As such, although the use of the NIs may not have slowed down transmission of A(H1N1)pdm09, they were effective in reducing hospitalizations and therefore decreasing the burden on the acute care sector.

Conclusions {#s4a}
-----------

Antiviral use in people with influenza who were at risk of severe disease or complications from influenza infection was associated with a reduced risk of hospitalization during the 2009 influenza pandemic. Antiviral strategies should continue to be incorporated into pandemic planning for future influenza pandemics.
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[^1]: Sample size (no. of hospitalizations): antiviral, 58 061 (304); non-antiviral, 58 061 (345).

[^2]: ^a^Indicating model was adjusted to non-proportionality, estimates unstable.

[^3]: ^b^Indicating whether the influenza referent date was during the period that vaccine became available on 26 October 2009.

[^4]: AV, antiviral.

[^5]: ^a^Indicating model was adjusted to non-proportionality, estimates unstable.
